메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

openRxiv names Dr. Tracy Teal first CEO to advance open science

[ 메디채널 김갑성 기자 ] Scientist and nonprofit leader who previously led The Carpentries and Dryad to lead the organization that oversees bioRxiv and medRxiv. DAVIS, Calif., Aug. 19, 2025 -- openRxiv announced today that after an extensive international search, its Board of Directors has appointed Dr. Tracy Teal as the organization's inaugural CEO. Dr. Teal has served as interim COO of openRxiv since its launch as an independent non-profit in March of this year, playing a central role in launching the organization and establishing its stewardship of bioRxiv and medRxiv, two of the world's m
- 김갑성 기자
- 2025-08-19 00:00
Ansell Receives Frost & Sullivan's 2025 Global Sustainable Hospital Supplies Company of the Year Award

[ 메디채널 김갑성 기자 ] Ansell is recognised for its leadership in hospital supply sustainability, visionary innovation, and customer impact on a global scale. SAN ANTONIO, Aug. 18, 2025 -- Frost & Sullivan, a leader in the information and growth advisory industry, has awarded the title of "2025 Global Sustainable Hospital Supplies Company of the Year" to Ansell, a global provider of safety solutions. Recognised for its outstanding achievements in innovation and customer impact, Ansell is focused on driving sustainable innovation by using fewer or safer materials and continuous
- 김갑성 기자
- 2025-08-18 22:00
Aon Announces Strategic Investment in eMed to Scale GLP-1 Population Health Platform

[ 메디채널 김갑성 기자 ] Strategic investment is accelerating the transformation of employer-focused obesity solutions to boost adherence, retention and deliver breakthrough health outcomes with cost savings DUBLIN, Aug. 18, 2025 -- Aon plc (NYSE: AON), a leading global professional services firm, today announced a strategic investment in eMed Population Health, Inc., an emerging leader in the delivery of GLP-1 programs. The partnership will enhance employer sponsored access to GLP-1 therapies and scale solutions for obesity. The investment follows the launch earlier this year of Aon's
- 김갑성 기자
- 2025-08-18 21:30
Datasea Achieves Breakthrough in Acoustic Technology, Accelerating Billion-Dollar Commercialization in Healthcare

DTSS' Acoustic innovation Addresses the Healthcare Application Market Projected to Exceed $100 Billion in China and Approach $90 Billion Globally by 2030 BEIJING, Aug. 18, 2025 -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada-based technology enterprise specializing in advanced acoustic high-tech products and AI multimodal digital solutions, today announced a milestone breakthrough in its acoustic technology. The Company has successfully achieved an exciting leap forward in its acoustic core technologies with the integration of sound wa
- 김갑성 기자
- 2025-08-18 21:30
Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).

[ 메디채널 김갑성 기자 ] This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted. DXVX is taking the lead in business development, with several companies in the due diligence stage, and additional deals are anticipated. SEOUL, South Korea, Aug. 18, 2025 -- Avixgen, a subsidiary of Dx&Vx, announced on the 18th that it has signed a licensing-out agreement worth approximately USD 360 million with a U.S. biotechnology company for its next-generation drug delivery platform, ACP (Advanced Cell Penetrating Pep
- 김갑성 기자
- 2025-08-18 21:00
LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company

BEIJING, Aug. 18, 2025 -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its board of directors (the "Board") has received a preliminary non-binding proposal letter (the "Proposal Letter"), dated August 18, 2025, from Oceanpine Investment Fund II LP and Oceanpine Capital Inc. (collectively, "Oceanpine
- 황정호 기자
- 2025-08-18 20:00
KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS

Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion Research and development expenses was approximately RMB611.5 million Loss for the period was RMB145.2 million; adjusted loss for the period[1] was RMB69.4 million Cash and cash equivalents[2] amounted to approximately RMB4527.8 million, reflecting ample cash reserves Note1: Calculated by deducting equity-settled share-based payment from loss for the year. Note2: Comprises cash and cash eq
- 김갑성 기자
- 2025-08-18 18:29
India's leading healthcare network Manipal Hospitals welcomes India's leading cancer specialist Dr. Surender Kumar Dabas to strengthen robotic cancer care in Delhi NCR

NEW DELHI, Aug. 18, 2025 -- Manipal Hospitals, one of India's leading and globally recognized healthcare institutions, welcomes one of India's most renowned robotic oncosurgeons, Dr. Surender Kumar Dabas as Chairman – Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster. With this addition, the hospital across Delhi, Gurugram and Ghaziabad further reinforces its vision to be a destination for world-class cancer care, catering to patients across India as well as international geographies. Dr. Surender Dabas brings with him more than 22
- 김갑성 기자
- 2025-08-18 18:23
GC Biopharma Signs MOU with Thai Red Cross Society to Strengthen Collaboration on Plasma-Derived Therapies

YONGIN, South Korea, Aug. 18, 2025 -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a Memorandum of Understanding (MOU) with the Thai Red Cross Society (TRCS) to cooperate on workforce training for the production of plasma-derived medicinal products. This MOU formalizes and deepens a relationship that began in 2015, when GC Biopharma supported TRCS to establish a plasma fractionation facility in Thailand, and reflects the ongoing strategic collaboration between the two parties. Under the terms of the
- 김갑성 기자
- 2025-08-18 12:40
Next Generation Refractive Surgery to LASIK and SMILE Now Available for Clinical Review

Pioneer surgeon Dr Natasha Lim is among the first in Singapore to offer Smooth Incision Lenticular Keratomileusis (SILK) procedure in their clinics. SINGAPORE, Aug. 18, 2025 -- Dr. Natasha Lim, an internationally renowned surgeon in Ophthalmology, has introduced an alternative to established refractive surgery techniques for medical practitioners in Singapore to explore. Smooth Incision Lenticule Keratomileusis (SILK), a recent advancement in laser vision correction, offers a potentially improved approach to correcting myopia and astigmatism. SILK is a flapless refractive surgery that
- 김갑성 기자
- 2025-08-18 11:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-09-05_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 05일 13시 00분